A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease
Part of paid clinical trials in Chula Vista, California.
- Sponsor
- Ingenia Therapeutics INC
- Study ID
- NCT07231679
- Phase
- PHASE1/PHASE2
- Status
- Recruiting
Conditions
- Chronic Kidney Disease
- Healthy Volunteers
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Accepted
Interventions
- IGT-303 — DRUGIGT-303 administered via IV or SC
- Placebo — DRUGSaline
Study Details
The goal of this clinical trial is to observe the safety of IGT-303 in healthy volunteers and participants with Chronic Kidney Disease. The main question it aims to answer is: Is IGT-303 safe as a single dose or multiple dose regimen when applied under the skin (subcutaneously (SC)) or to a vein (intravenously (IV)). Researchers will compare IGT-303 against a placebo to see if IGT-303 is safe for use. Participants will be assigned to either IGT-303 or placebo and assessed for safety and tolerability for the duration of the study.
Key Dates
- First listed
- Nov 17, 2025
- Start date
- Oct 30, 2025
- Status verified
- Oct 2026
- Primary completion
- Dec 31, 2026
- Completion
- Apr 30, 2027
Study Design
- Enrollment
- 94 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: IGT-303Part A: single ascending dose (SAD), 6 cohorts Part B: multiple ascending dose (MAD), 3 cohorts
- Placebo Comparator: PlaceboPlacebo (normal saline)
Primary Outcome Measure
Adverse events (AEs), serious adverse events (SAEs), and treatment-emergent adverse events (TEAEs) [ Time Frame: From Screening to Day 84. ]
Central Contacts
- Jennifer Curry, PharmD317-726-9118
- Jinsam You, PhD617-440-2518
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Balboa Nephrology - Chula Vista | Chula Vista | California | 91910 | - |
| Clinical Research of Central Florida | Lakeland | Florida | 33805 | - |
| Piedmont HealthCare | Statesville | North Carolina | 28625 | - |
| Wilmington Health | Wilmington | North Carolina | 28412 | - |
Find similar trials in Chula Vista, CA
By condition
By specialty
Related Studies
- Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal CenterEnrolling By Invitation · University of Michigan · Ann Arbor, Michigan
- Senescence in Chronic Kidney DiseasePHASE2 · Enrolling By Invitation · Mayo Clinic · Jacksonville, Florida
- A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on HemodialysisPHASE3 · Recruiting · Amgen · Los Angeles, California
- A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and ProteinuriaPHASE3 · Recruiting · Bayer · Phoenix, Arizona